FDA's response wasn't what they expected: the agency had no established basis for believing that biomarker actually tracked with how patients felt or functioned day to day, and without that link, a clean p-value wasn't going to carry the program. The sponsor had generated rigorous evidence. It just wasn't evidence anyone downstream could act on. What followed was roughly 18 months retrofitting a patient-reported outcome measure into the confirmatory study a fix that would have cost a fraction of the time and money if someone had raised the question before the trial was designed around that endpoint in the first place.
-
2 Posts
-
1 Photos
-
0 Videos
-
Lives in USA
-
From USA
-
Male
-
02/02/1991
-
Followed by 0 people
Recent Updates
-
Salience Clinical White Paper SeriesPsilocybin at a Regulatory Crossroads: Five Unresolved Questions Shaping the Future of Psychedelic Medicine Denis Katz, M.D. Founder & Medical Director, Salience Clinical LLC Introduction The optimism surrounding psilocybin is not unfounded. Early clinical findings have been striking enough to attract serious scientific attention, substantial investment, and a level of public interest that...0 Comments 0 Shares 389 Views 0 ReviewsPlease log in to like, share and comment!
-
0 Comments 0 Shares 239 Views 0 Reviews
More Stories